BioMarin Pharmaceutical Inc. — Ethics Grade C-

BioMarin Pharmaceutical Inc. receives an overall ethics grade of C- (48/100) on CancelCo's corporate accountability database. Sector: Pharmaceuticals. Market cap: Large Cap.

Category scores

• labor: 50
• privacy: 80
• consumer: 40
• environment: 75
• humanRights: 60

Documented incidents (3)

• Palynziq Pricing Criticism (medium, 2018) — The company faced significant backlash for the pricing of its drug Palynziq, which was launched at approximately $192,000 per year, raising concerns about the sustainability of orphan drug costs.
• FDA Rejection of Valoctocogene Roxaparvovec (high, 2020) — BioMarin faced investor lawsuits after the FDA unexpectedly rejected its gene therapy for hemophilia A, citing the need for two years of additional data which the company allegedly downplayed.
• Employee Non-Solicitation Settlement (medium, 2022) — BioMarin was part of a group of life sciences companies that settled allegations regarding 'no-poach' agreements that restricted employee mobility and suppressed wages.

Documented good deeds

• Expanded Access Programs — Implemented a global expanded access program providing investigational therapies to patients with serious rare diseases who lack other options.

Ethical alternatives

• Vertex Pharmaceuticals — Better record on clinical trial transparency and focused gene therapy ethics.